The developers of a potential COVID-19 antibody treatment have moved trials to a third phase, hailing “rapid achievement” with no safety concerns to date.
The world’s largest vaccines player, GlaxoSmithKline (GSK), and Vir Biotechnology said their trial programme was also to be expanded across new sites in North America, South America and Europe.
The pair have been working on an antibody-based treatment since April, while GSK has a separate vaccine partnership with Sanofi that entered clinical trials last month.
It is hoped that the Comet-Ice trial under development with Vir, which began human testing in August, will enable early treatment of the coronavirus in high-risk patients by killing affected cells.
The companies have also pointed to encouraging results in resistance and protection of the lungs in the 20 patients with the disease to have taken part so far.
I run this site in my spare time and thoroughly enjoy giving you all positive news! If you’ve enjoyed the site we’d love for you to help me share the good news far and wide, share us on Reddit, your Facebook or your Twitter and spread a little positivity around.
ENJOY FEEL GOOD, INSPIRING STORIES AND VIDEOS ?
Our new page here is just what you need, with just good news, feel good stories unrelated to COVID.